How to Apply for the Sai Parenterals Limited IPO: Step-by-Step Investment Guide

Summary:


Sai Parenteral’s Ltd. is a pharmaceutical formulations company engaged in research, development, and manufacturing activities. The Sai Parenteral’s Limited IPO is scheduled to open on March 24, 2026, and close on March 27, 2026. The issue comprises 1,04,28,288 shares with a price band of ₹372 to ₹392 per share and is proposed to be listed on the stock exchanges, subject to applicable approvals. The IPO includes provisions for different investor categories and outlines the company’s participation in both domestic and international pharmaceutical markets.

Sai Parenteral’s Ltd. operates in the pharmaceutical formulations segment with activities across research, development, and manufacturing. The company’s operations are divided into branded generic formulations and contract development and manufacturing organisation (CDMO) services, catering to domestic and international markets. Its product portfolio includes formulations across therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, dermatology, and vitamins, minerals, and supplements. These products are available in multiple dosage forms, including injectables, tablets, capsules, liquid orals, and ointments, indicating a diversified product presence. The company supplies its products to government institutions, pharmaceutical companies, hospitals, and distribution networks. It has also entered export markets following the acquisition of internationally accredited facilities, enabling supply to regulated and semi-regulated regions. Its manufacturing network includes multiple facilities with GMP and WHO-GMP certifications, supporting its operational capabilities.

To apply for the Sai Parenteral’s IPO, investors can use the ASBA (Application Supported by Blocked Amount) facility through their bank account or apply via UPI-enabled platforms offered by stockbrokers. The process involves selecting the IPO, entering bid details such as quantity and price within the specified band, and authorising the payment request. The application amount remains blocked in the bank account until allotment is finalised, in accordance with regulatory processes. Alternatively, investors may apply through online trading platforms by logging into their account, selecting the IPO section, and submitting the application using UPI authentication. It is necessary to ensure that the demat account details, PAN, and bank information are correctly updated before placing the bid. The allotment status can be checked after the basis of allotment is finalised, and shares, if allotted, are credited to the demat account as per the applicable timelines.

For more details, visit the Sai Parenterals Limited IPO page.

Sai Parenterals Limited IPO Details and Objectives

Details

Information

IPO Date

Mar 24, 2026 to Mar 27, 2026

Issue Size

1,04,28,288 shares (agg. up to ₹409 Cr)

Price Band

₹372 to ₹392 per share

Lot Size

38 shares

Listing At

BSE NSE

Purpose of the IPO

  • Capacity expansion and upgradation of manufacturing facilities

  • Establishment of a new R&D centre

  • Repayment / prepayment of certain outstanding borrowings

  • Working capital requirements

  • Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenteral’s Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia)

  • General corporate purposes

Timeline of Sai Parenterals Limited IPO

Event

Date

IPO Open Date

Tue, Mar 24, 2026

IPO Close Date

Fri, Mar 27, 2026

Tentative Allotment

Mon, Mar 30, 2026

Initiation of Refunds

Wed, Apr 1, 2026

Credit of Shares to Demat

Wed, Apr 1, 2026

Tentative Listing Date

Thu, Apr 2, 2026

Cut-off time for UPI mandate confirmation

5 PM on Fri, Mar 27, 2026

Pricing & Lot Size of Sai Parenterals Limited IPO

Price Band for the IPO

  • ₹372 to ₹392 per share

Minimum Lot Size and Application Details

Application

Lots

Shares

Amount

Retail (Min)

1

38

₹14,896

Retail (Max)

13

494

₹1,93,648

S-HNI (Min)

14

532

₹2,08,544

S-HNI (Max)

67

2,546

₹9,98,032

B-HNI (Min)

68

2,584

₹10,12,928

Sai Parenterals Limited IPO Application Process

The Sai Parenteral’s Limited IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:

Step 1: Login to Your Trading Platform

Access your trading account using the broker's app or website.

Step 2: Navigate to the IPO Section

Go to the IPO section to view active IPO listings.

Step 3: Select the Open IPO and Click Apply

Locate Sai Parenteral’s Limited IPO in the list of available IPOs and click the ‘Apply’ button.

Step 4: Enter the Quantity of Shares You Wish to Apply For

Specify the number of shares (lot size: 38 shares) within the price band of ₹372 to ₹392 per share.

Step 5: Provide Your UPI ID

Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.

Step 6: Confirm the Application

Review your application details and confirm the UPI mandate before 5 PM on the last application day.

Step 7: Complete the Process and Wait for Allotment

Submit the application and monitor the allotment status to check if shares have been allocated to you.

Shares Offered in Sai Parenterals IPO

The allocation of shares in the Sai Parenteral’s IPO is structured across investor categories in line with applicable regulatory requirements. The issue provides defined reservations for qualified institutional buyers, non-institutional investors, and retail individual investors, with each category allotted a specified proportion of the net issue. This allocation framework outlines how the shares offered are distributed among different classes of investors.

Investor Category

Shares Offered

Anchor Investors

31,28,486 (30.00%)

Non-Institutional Investor

15,64,243 (15.00%)

Qualified Institutional Buyers

20,85,658 (20.00%)

Retail Individual Investor

36,49,901 (35.00%)

Total Shares Offered

1,04,28,288 (100.00%)

This reservation structure reflects the categorisation and allocation approach disclosed for the issue, indicating the proportion of shares available to each investor segment.

Financial Health and Performance

Key Financial Metrics

  • Total Assets: Grew from ₹133.96 crore in FY23 to ₹376.24 crore as of Sept 2025.

  • Total income: Recorded at ₹89.43 crore in Sept 2025, as compared to ₹97.03 crore in FY23.

  • Profit After Tax (PAT): Reported at ₹7.76 crore in Sept 2025, and ₹4.38 crore in FY23.

  • Net Worth: Recorded at ₹209.37 crore in Sept 2025 in comparison to ₹31.49 crore in FY23.

  • Reserves & Surplus: Stood at ₹188.84 crore in Sept 2025, as compared to ₹24.34 crore in FY23.

  • Total Borrowing: Stood at ₹76.07 crore in Sept 2025, as compared to ₹68.55 crore in FY23.

  • EBITDA: Stood at ₹16.24 crore in Sept 2025 in comparison to ₹17.64 crore in FY23.

Recent Performance and Growth Prospects

  • The company has reported an expansion in its asset base over the reviewed period, indicating scale-up in operations and infrastructure.

  • Total income reflects some variation across reporting periods, suggesting changes in revenue momentum.

  • Profit after tax shows an improvement, indicating changes in overall profitability during the period under review.

  • Net worth has increased over time, reflecting changes in the company’s financial position.

  • Reserves and surplus have also risen, indicating accumulation of retained earnings.

  • Total borrowings have increased, reflecting utilisation of external funding to support operations or expansion activities.

  • EBITDA reflects variation across periods, indicating changes in operating performance.

  • Overall, the financial profile indicates developments in scale, capital structure, and operational performance, based on available data.

Investment Risks and Opportunities

Potential Risks of Investing in the IPO

  • Variations in total income and EBITDA across reporting periods indicate changes in revenue generation and operating performance, which may reflect fluctuations in business activity.

  • An increase in total borrowings suggests reliance on external funding, which may have implications for financial obligations and capital structure management.

Opportunities and Growth Potential

  • The company operates across branded generics and CDMO segments, with a diversified product portfolio spanning multiple therapeutic areas and dosage forms, indicating broad participation in the pharmaceutical formulations market.

  • Planned utilisation of IPO proceeds towards capacity expansion, research and development, and entry into international markets reflects initiatives aligned with operational scale and market presence.

Key Performance Indicator (KPI)

KPI

Sept 30, 2025

Mar 31, 2025

ROE

5.13%

16.82%

ROCE

9.28%

28.92%

RoNW

5.09%

15.09%

PAT Margin

8.93%

8.88%

EBITDA Margin

18.68%

24.18%

Price to Book Value

 

10.89

Sai Parenterals Limited IPO Registrar & Lead Managers

Registrar

Lead Manager(s)

Bigshare Services Pvt.Ltd.

Arihant Capital Markets Ltd.

Company Address of Sai Parenterals Limited

Plot No. 39

5th floor, Lavanya Arcade Jayabheri Enclave

Gachibowli, K.V. Rangareddy, Seri Lingampally

Hyderabad, Telangana, 500032

Phone: +91 79979 91301

Email: cs@saiparenterals.com

Website: https://www.saiparenterals.com/

Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Sai Parenterals IPO allotment status.

Who is the CEO of Sai Parenterals Ltd?

Anil Kumar Karusala is the Chairman and Managing Director of Sai Parenteral’s Ltd.

When will the Sai Parenterals IPO open for subscription?

The Sai Parenteral’s IPO is scheduled to open for subscription on March 24, 2026, and will close on March 27, 2026, as per the disclosed timeline.

What is the company’s core business, and how sustainable is its business model in the long term?

Sai Parenteral’s Ltd operates in the pharmaceutical formulations segment with activities across research, development, and manufacturing. Its operations include branded generic formulations and contract development and manufacturing organisation (CDMO) services for domestic and international markets. The company’s diversified product portfolio and presence across multiple therapeutic areas reflect its participation in different segments of the pharmaceutical value chain. Any assessment of long-term sustainability would depend on multiple factors, including regulatory environment, market conditions, and operational performance.

What is the issue size of the Sai Parenterals IPO?

The IPO comprises 1,04,28,288 shares, aggregating up to approximately ₹409 crore, based on the disclosed issue details.

What is 'pre-apply' for the Sai Parenterals IPO?

‘Pre-apply’ refers to the facility that allows investors to submit their application for an IPO before the official opening date. The application is processed once the IPO opens, in accordance with applicable procedures.

What is the lot size and minimum order quantity of the Sai Parenterals IPO?

The minimum lot size for the Sai Parenteral’s IPO is 38 shares. Retail investors are required to apply for at least one lot, which represents the minimum order quantity.

What is the allotment date for the Sai Parenterals IPO?

The tentative allotment date for the Sai Parenteral’s IPO is March 30, 2026, based on the disclosed schedule.

Who is the registrar of Sai Parenterals IPO?

The registrar for Sai Parenteral’s IPO is Bigshare Services Pvt. Ltd., as per the provided information.

Are there any governance issues or red flags in the company’s leadership or board structure?

There are no publicly stated governance issues or red flags highlighted. Investors may review the offer documents, including sections on management, board composition, and risk factors, for detailed and verified disclosures.

What is the process to apply for the Sai Parenterals IPO?

Investors can apply for the IPO through the ASBA facility using their bank account or via UPI-enabled platforms provided by trading applications. The process involves selecting the IPO, entering bid details such as quantity and price within the specified range, and authorising the payment request. The application amount remains blocked until the allotment process is completed.

Do I need a Demat account to apply for the Sai Parenterals IPO?

Yes, a Demat account is required to apply for the IPO, as shares, if allotted, are credited in electronic form to the applicant’s Demat account.

How will I know if my application for the Sai Parenterals IPO has been successful?

Investors can check the allotment status once it is finalised, typically through the registrar’s website or the trading platform used for application. If shares are allotted, they are credited to the Demat account, and the status is updated accordingly.

Published Date : 24 Mar 2026

Disclaimer :

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 lakh+ Users

icon-with-text

4.7 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,300+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|